Sanofi loses preemption argument ahead of cancer drug Taxotere bellwether trial
New Delhi: Federal law does not shield Sanofi from a woman's claim that it failed to warn her that its cancer drug Taxotere could cause permanent hair loss, a federal court has ruled, a victory for the plaintiff in the second bellwether trial scheduled in a multidistrict litigation over the drug.
Read also: Sanofi wins EU approval for Dupixent for atopic dermatitis in children
U.S. District Judge Jane Triche Milazzo in New Orleans on Friday rejected Sanofi's argument that it could not have revised its FDA-approved label, which did not warn of permanent hair loss, at the time of plaintiff Elizabeth Kahn's Taxotere treatment in 2008.
Read also: Sanofi, GSK delay Covid vaccine program to improve immune response
Next Story
